Clinical Trial Update: Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of NTQ5082 capsules for Primary IgA Nephropathy; enrollment has not started yet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• NTQ5082

Snippet

Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical | Conditions: Primary IgA Nephropathy | Phase 2 | Status: NOT_YET_RECRUITING